Abstract
Abstract
Background
Sarcomatoid carcinoma of the pancreas (SCP) is a rare type of malignant pancreatic neoplasm, and its prognosis is even worse than that of conventional pancreatic ductal adenocarcinoma (PDAC). Currently, there is no standard regimen for treating SCP, and the impact of systemic therapy on the survival of patients with SCP has not been well defined.
Case presentation
Herein, we report a 38-year-old Asian man diagnosed of local unresectable SCP with supraclavicular lymph node metastasis, radical excision after camrelizumab and anlotinib therapy, which resulted in a remarkable reduction in the size of primary tumor and complete remission of the metastatic lymph node.
Conclusions
This is the first report of the use of immunotherapy and anti-angiogenesis therapy in a patient with SCP, which provides optimistic data to support the synergistic effect.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Gill AJ, Klimstra DS, Lam AK, et al. Tumours of the pancreas. In: Lokuhetty D, White VA, Watanabe R, Cree IA, editors. World Health Organization Classification of Tumours, Digestive System Tumours, 5th edn. Lyon: IARC; 2019. pp. 295–372.
2. Blair AB, Burkhart RA, et al. Long-term survival after resection of sarcomatoid carcinoma of the pancreas: an updated experience. J Surg Res. 2017;219:238–43.
3. Uenishi T, Hirohashi K, Kubo S, et al. A pancreatic anaplastic carcinomaofspindle-cellform. Int J Pancreatol. 1999;26:201–4.
4. Higashi M, Takao S, Sato E. Sarcomatoid carcinoma of the pancreas: a case report with immunohistochemical study. Pathol Int. 1999;49:453–6.
5. De la Riva S, Muñoz-Navas MA, Betés M, et al. Sarcomatoid carcinoma of the pancreas and congenital choledochal cyst. Gastrointest Endosc. 2006;64:1005–6.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献